Press release
Candidemia Pipeline, NDA Approvals, Clinical Trials Assesment 2023 (Updated) | Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others
DelveInsight's "Candidemia Pipeline Insight 2023" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Candidemia pipeline landscape. It covers the Candidemia pipeline drug profiles, including Candidemia clinical trials and nonclinical stage products. It also covers the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Recent Developmental Activities in the Candidemia Treatment Landscape
• On 23 March 2023, Rezafungin for injection, also known as REZZAYOTM, is now licensed by the U.S. Food and Drug Administration (FDA) as a treatment for candidemia and invasive candidiasis. The new medication is the first to be approved in more than ten years for the invasive fungal illness. It is a brand-new antifungal treatment administered intravenously once every week.
• In April 2022, the US FDA approved VIVJOA (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC), also referred to as chronic yeast infection.
• In June 2021, the US FDA approved BREXAFEMME (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC). It is a novel class of antifungal and the first and only oral fungicidal treatment that can cure a vaginal yeast infection in adults and postmenarchal pediatric patients. Recently, a supplemental New Drug Application (sNDA) to the US FDA of an additional indication i.e. for the prevention of recurrent vulvovaginal candidiasis (RVVC) was submitted.
Discover the recent breakthroughs happening in the Candidemia Pipeline landscape @ Candidemia Pipeline Outlook- https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Candidemia Pipeline Report
• DelveInsight's Candidemia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Candidemia treatment.
• The leading Candidemia Companies include Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others
• Promising Candidemia Pipeline Therapies include ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others
• The Candidemia companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The Candidemia therapies under development are focused on novel approaches to treat/improve Candidemia.
Candidemia Emerging Drugs Profile
• Rezafungin: Cidara Therapeutics
Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. For the treatment of candidemia and invasive candidiasis, rezafungin has designations for Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in the United States from the time of FDA approval. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Candidemia.
Get More Information on the Candidemia Drugs and Companies of Report @ Candidemia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Candidemia Pipeline Report
• Coverage- Global
• Candidemia Companies- Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others.
• Candidemia Pipeline Therapies- ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others.
• Candidemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Find out more about the list of FDA-approved drugs for Candidemia @ Candidemia Treatment Landscape- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Candidemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Rezafungin: Cidara Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. APX001: Amplyx Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Candidemia Key Companies
17. Candidemia Key Products
18. Candidemia- Unmet Needs
19. Candidemia- Market Drivers and Barriers
20. Candidemia- Future Perspectives and Conclusion
21. Candidemia Analyst Views
22. Candidemia Key Companies
23. Appendix
Got Queries? Find out the related information on Candidemia Preclinical and Discovery Stage Products @ Candidemia Drugs, Unmet Needs, and Recent Trends- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Candidemia Pipeline, NDA Approvals, Clinical Trials Assesment 2023 (Updated) | Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others here
News-ID: 3128786 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Candidemia
Candidemia Market Growth, Trends, Consumer Demand and Key Opportunities
Introduction
Candidemia, a bloodstream infection caused by Candida species, is one of the most severe forms of invasive candidiasis. It represents a major healthcare challenge worldwide, particularly in immunocompromised individuals, intensive care unit (ICU) patients, and those with central venous catheters. The infection is associated with high morbidity, mortality, and healthcare costs, making it a critical focus of antifungal research and hospital infection control programs.
The market is shaped by rising prevalence…
Candidemia Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incid …
Candidemia companies working in the market are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Scynexis, Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, and others.
(Albany, USA) DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Candidemia Market Size is Set for Rapid Growth as Innovative Treatments and Risi …
The Candidemia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Cidara Therapeutics, Mycovia Pharmaceuticals, Scynexis, GSK, Basilea Pharmaceutica, Pfizer, Astellas Pharma Inc, Gilead Sciences, Scynexis, Inc., Merck Sharp & Dohme LLC
[Nevada, United States] - DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Candidemia, covering historical…
Candidemia Market Size Report 2032 | Market Drivers & Barriers, Clinical Trials …
(Albany, USA) DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Candidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Candidemia market size from 2019 to…
Candidemia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, R …
The Candidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Candidemia pipeline products will significantly revolutionize the Candidemia market dynamics.
DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Candidemia Market Report 2024-2034, Industry Size, Share, Trends and Future Grow …
Candidemia Market Size:
The candidemia market are expected to exhibit a CAGR of 3.16% during 2024-2034. The candidemia market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven…